Suzhou Alphamab Co., Ltd.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS6
PHASE 3 / 2-33
RECRUITING2
READOUTS ≤12 MONTHS1
READOUT SLIPPED >6 MO0%
Delay Index: of 5 active trials registered more than a year ago, 0 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →
Open Suzhou Alphamab Co., Ltd. on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| KN057 NCT06312475 |
P3 | Active, not recruiting | Hemophilia A With Inhibitor; Hemophilia B With Inhibitor | 53 | 2025-10-15 |
| Enoxaparin NCT06180889 |
P2 | Active, not recruiting | Knee Arthroplasty, Total | 241 | 2025-12-15 |
| KN057 NCT06747416 |
P2 | Not yet recruiting | Hemophilia a and B | 24 | 2026-09-02 |
| KN057 NCT06569108 |
P3 | Active, not recruiting | Hemophilia A Without Inhibitor; Hemophilia B Without Inhibitor | 125 | 2026-10-15 |
| KN060 NCT07201467 |
P1/2 | Recruiting | End-Stage Renal Disease Requiring Haemodialysis | 12 | 2027-08-15 |
| KN057 NCT07545395 |
P3 | Recruiting | Hemophilia A or B | 70 | 2027-12-30 |